What do Formula One racing drivers and clinical scientists have in common? Short answer: sensors and big data.
McLaren is a world force in Formula One racing, but the UK-based company is less known for its Internet of Things capabilities. Over the last two decades, McLaren took advantage of the natural convergence between data management, predictive analytics, and embedded electronics to ensure its success on the track. Over the course of a typical grand prix weekend the McLaren racing team will capture more than a billion data points from the 200+ sensors located on each car. Using telemetry and algorithms to monitor the health of their race cars, engineers and strategists can make informed decisions in real-time.
This technology is now the foundation for McLaren Applied Technology’s significant work in healthcare. Partnering with GSK, McLaren is in pole position to find new ways to use biosensors and mobile health platforms to improve patient care. More specifically, the two companies joined forces to develop biotelemetry technology that can measure 24/7 the vital signs and mobility of patients involved in drug trials for ALS, stroke-recovery and asthma. The data, streamed in real-time from patients, allows researchers to determine more quickly if a drug is or isn’t working, or is causing troubling side effects.
Using this type of technology benefits patients in other ways too: it can mean fewer trips to the clinic as biosensor devices can be used for remote monitoring. The end result is a much more robust collection of data with minimal interruption to a patient’s day-to-day life. In the long run, this personalized approach to patient care could save time, money and, most importantly, lives.